Suche
Mein Konto
Bayer shares on the brink of further decline: patent loss weighs on the pharmaceutical industry
Find out why shorting Bayer shares on April 23, 2024 could be a worthwhile strategy. Dividends, patent losses and industry comparisons in focus. Find out now!
Bayer shares on the brink of further decline: patent loss weighs on the pharmaceutical industry
According to experts, the recent recovery in Bayer shares may not last. In the coming days, Bayer plans to pay a dividend of 11 cents, which corresponds to a yield of just half a percent. The current price of the share is at a new interim low as negative news is weighing on the company.
A patent court in London recently invalidated a patent for an anticoagulant, which could mean a bitter loss for Bayer. In particular, the drug Xarelto, which generates around $4 billion in sales annually, is in focus. In addition, the follow-up drug Asundexian had to be discontinued prematurely due to lack of effectiveness.
Compared to its competitors, Boehringer Ingelheim was able to finish last year as the German pharmaceutical company with the highest sales, with sales increasing by 10%. In contrast, Bayer reported a 6% decline in sales. Experts at Tradespot therefore foresee further weakness in Bayer shares and recommend a short trade.
For investors who want to benefit from price weakness, the use of put warrants is recommended. Due to the lower volatility of Bayer shares, possible daily fluctuations can be better balanced out with a put warrant. Investors can discover the use of such trading ideas and much more in the new tradespot app from finanzen.net. Trading spots offer exclusive ideas and insights presented by stock market experts and analysts.